Cargando…
Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit
INTRODUCTION: Liraglutide 3.0 mg, a glucagon-like peptide-1 (GLP-1) analogue, is a medication approved for obesity treatment. This study aimed to investigate the relationship between psychiatric symptoms, including depression, anxiety, and binge eating, and their impact on therapy adherence. METHODS...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684642/ https://www.ncbi.nlm.nih.gov/pubmed/38015342 http://dx.doi.org/10.1007/s40519-023-01625-5 |
_version_ | 1785151448706711552 |
---|---|
author | Tempia Valenta, Silvia Stecchi, Michele Perazza, Federica Nuccitelli, Chiara Villanova, Nicola Pironi, Loris Atti, Anna Rita Petroni, Maria Letizia |
author_facet | Tempia Valenta, Silvia Stecchi, Michele Perazza, Federica Nuccitelli, Chiara Villanova, Nicola Pironi, Loris Atti, Anna Rita Petroni, Maria Letizia |
author_sort | Tempia Valenta, Silvia |
collection | PubMed |
description | INTRODUCTION: Liraglutide 3.0 mg, a glucagon-like peptide-1 (GLP-1) analogue, is a medication approved for obesity treatment. This study aimed to investigate the relationship between psychiatric symptoms, including depression, anxiety, and binge eating, and their impact on therapy adherence. METHODS: A clinical audit was carried out on a cohort of 54 adults with obesity treated with liraglutide 3.0 mg. We retrospectively analyzed the connection between psychiatric symptoms assessed through the State-Trait Anxiety Inventory (STAI), Beck Depression Inventory (BDI), and Binge Eating Scale (BES). Adherence to therapy was assessed by the maximum dosage (MD) and treatment duration (TD). RESULTS: Notably, a discontinuation rate of 59% was encountered. However, among those who continued the treatment, we observed a negative association between anxiety symptoms (STAI score) and MD, depression symptoms (BDI score) and TD, and a higher likelihood of binge eating (BES score > 17) and TD. Moreover, presence of psychiatric symptoms did not compromise drug's effectiveness in achieving weight loss, which was 4.43% (± 5.5 SD) in the whole sample and 5.3% (± 6.3 SD) in the subgroup evaluated at 12 weeks. CONCLUSION: We observed a high discontinuation rate in real-life clinical setting, where Liraglutide 3.0 therapy is paid out-of-pocket. While psychiatric symptoms might play a role in diminishing adherence to therapy, they do not prevent drug's effectiveness to promote weight loss. This finding underscores the potential advantages of liraglutide 3.0 mg therapy for individuals contending with obesity while simultaneously managing mental health challenges. LEVEL OF EVIDENCE: Level V, descriptive studies. |
format | Online Article Text |
id | pubmed-10684642 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-106846422023-11-30 Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit Tempia Valenta, Silvia Stecchi, Michele Perazza, Federica Nuccitelli, Chiara Villanova, Nicola Pironi, Loris Atti, Anna Rita Petroni, Maria Letizia Eat Weight Disord Research INTRODUCTION: Liraglutide 3.0 mg, a glucagon-like peptide-1 (GLP-1) analogue, is a medication approved for obesity treatment. This study aimed to investigate the relationship between psychiatric symptoms, including depression, anxiety, and binge eating, and their impact on therapy adherence. METHODS: A clinical audit was carried out on a cohort of 54 adults with obesity treated with liraglutide 3.0 mg. We retrospectively analyzed the connection between psychiatric symptoms assessed through the State-Trait Anxiety Inventory (STAI), Beck Depression Inventory (BDI), and Binge Eating Scale (BES). Adherence to therapy was assessed by the maximum dosage (MD) and treatment duration (TD). RESULTS: Notably, a discontinuation rate of 59% was encountered. However, among those who continued the treatment, we observed a negative association between anxiety symptoms (STAI score) and MD, depression symptoms (BDI score) and TD, and a higher likelihood of binge eating (BES score > 17) and TD. Moreover, presence of psychiatric symptoms did not compromise drug's effectiveness in achieving weight loss, which was 4.43% (± 5.5 SD) in the whole sample and 5.3% (± 6.3 SD) in the subgroup evaluated at 12 weeks. CONCLUSION: We observed a high discontinuation rate in real-life clinical setting, where Liraglutide 3.0 therapy is paid out-of-pocket. While psychiatric symptoms might play a role in diminishing adherence to therapy, they do not prevent drug's effectiveness to promote weight loss. This finding underscores the potential advantages of liraglutide 3.0 mg therapy for individuals contending with obesity while simultaneously managing mental health challenges. LEVEL OF EVIDENCE: Level V, descriptive studies. Springer International Publishing 2023-11-28 2023 /pmc/articles/PMC10684642/ /pubmed/38015342 http://dx.doi.org/10.1007/s40519-023-01625-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Tempia Valenta, Silvia Stecchi, Michele Perazza, Federica Nuccitelli, Chiara Villanova, Nicola Pironi, Loris Atti, Anna Rita Petroni, Maria Letizia Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit |
title | Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit |
title_full | Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit |
title_fullStr | Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit |
title_full_unstemmed | Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit |
title_short | Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit |
title_sort | liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? insights from a clinical audit |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684642/ https://www.ncbi.nlm.nih.gov/pubmed/38015342 http://dx.doi.org/10.1007/s40519-023-01625-5 |
work_keys_str_mv | AT tempiavalentasilvia liraglutide30mgandmentalhealthcanpsychiatricsymptomsbeassociatedtoadherencetotherapyinsightsfromaclinicalaudit AT stecchimichele liraglutide30mgandmentalhealthcanpsychiatricsymptomsbeassociatedtoadherencetotherapyinsightsfromaclinicalaudit AT perazzafederica liraglutide30mgandmentalhealthcanpsychiatricsymptomsbeassociatedtoadherencetotherapyinsightsfromaclinicalaudit AT nuccitellichiara liraglutide30mgandmentalhealthcanpsychiatricsymptomsbeassociatedtoadherencetotherapyinsightsfromaclinicalaudit AT villanovanicola liraglutide30mgandmentalhealthcanpsychiatricsymptomsbeassociatedtoadherencetotherapyinsightsfromaclinicalaudit AT pironiloris liraglutide30mgandmentalhealthcanpsychiatricsymptomsbeassociatedtoadherencetotherapyinsightsfromaclinicalaudit AT attiannarita liraglutide30mgandmentalhealthcanpsychiatricsymptomsbeassociatedtoadherencetotherapyinsightsfromaclinicalaudit AT petronimarialetizia liraglutide30mgandmentalhealthcanpsychiatricsymptomsbeassociatedtoadherencetotherapyinsightsfromaclinicalaudit |